A longitudinal study involving 436 patients with chronic GVHD found that patients with sclerotic and combination disease had worse symptoms and quality-of-life impairment compared to those with epidermal disease. The study used two validated patient-reported outcome tools to measure these factors. PROs were also found to predict non-relapse mortality for all three disease subtypes, indicating their potential use in risk stratification and treatment decisions. The study highlighted the importance of patient-reported outcomes in assessing chronic GVHD, especially for patients with sclerotic disease. Future research will focus on determining the most clinically relevant PROs for patients with chronic GVHD.
Source link
Patient-Reported Outcomes Important in Cutaneous GVHD: Study
